Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...
Jerold Chun, MD, PhD, is a professor in the Center for Neurologic Diseases at Sanford Burnham Prebys and the senior and corresponding author of the manuscript. Alzheimer’s disease is the most common ...
Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 83, No. 16 (Aug. 15, 1986), pp. 5919-5923 (5 pages) Yeast cells contain a protein of molecular size 70 kDa that ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the repeatome for drug development, today announced new preclinical data demonstrating the ability of ...
Crossbow Therapeutics Inc. has provided details on the preclinical characterization for the telomerase reverse transcriptase (TERT)-targeting T-cell engager CBX-663.
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
Prime editing uses CRISPR-guided reverse transcription to enable the programmable introduction of any desired base substitution or small insertion or deletion. One challenge for using prime editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback